Sign in

    Elizabeth Webster

    Research Analyst at Goldman Sachs

    Elizabeth Webster is an Equity Research Associate Analyst at Goldman Sachs, specializing in equity research across targeted industry sectors. She provides analytical coverage and investment insights on key companies relevant to her assigned industries, supporting senior analysts in producing detailed reports and recommendations. Elizabeth began her career at Goldman Sachs, developing expertise in financial modeling and in-depth industry analysis, and has contributed to the firm's research efforts since joining. She holds relevant professional credentials to operate in regulated financial roles at the firm.

    Elizabeth Webster's questions to Taysha Gene Therapies (TSHA) leadership

    Elizabeth Webster's questions to Taysha Gene Therapies (TSHA) leadership • Q2 2024

    Question

    Elizabeth Webster, on for Salveen Richter, inquired about the status of dialogue with regulatory authorities.

    Answer

    CEO Sean Nolan reported that Taysha has an upcoming Type B meeting with the FDA, a result of its RMAT designation. The key goals are to align on the cadence of interactions, share incoming clinical and natural history data in near real-time, and use this information to inform the trial design and endpoints for Part B of the study. He indicated that updates on this front would be provided in the coming quarter.

    Ask Fintool Equity Research AI